This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

		Start the program at the bottom of this page

Targeting the Tumor: Treating the Subtypes of Metastatic Breast Cancer Release Date: January-24-12 Credit Expiration Date: January-23-13 . This educational activity is designed to meet the needs of oncologists and those who manage patients with cancer. 0.25 AMA PRA Category 1 Credit™ Mobile + Online on QuantiaMD Breast cancer is the most frequently diagnosed and the second leading cause of cancer death in women. This year in the United States, an estimated 207,090 new cases of invasive breast cancer will be diagnosed in women, and an estimated 40,230 women will die from breast cancer. Oncologists play a critical role in improving outcomes in women with metastatic breast cancer (MBC). However, many oncologists have not updated their practices based on the latest clinical evidence in order to provide optimal care. Oncologists and others caring for women with MBC have the opportunity to improve outcomes in women with MBC by more effectively using biomarkers and genomic assays to quantify individual patient risk and guide treatment selection and by more thoroughly incorporating latest clinical evidence into treatment plans for each unique subset of MBC. The goal of this continuing medical education activity is to enhance the ability of oncologists to develop optimal treatment plans while integrating the latest clinical evidence into clinical practice, ultimately improving outcomes in women with MBC. Upon completion of this educational activity, the participant should be able to: 1. Describe the evolving role of targeted therapies for the treatment of advanced breast cancer. 2. Explain the optimal use of combination therapy for patients with advanced breast cancer. Maura N. Dickler, MD Associate Professor of Medicine Memorial Sloan-Kettering Cancer Center Weill Cornell Medical College New York, NY It is policy at the Perelman School of Medicine at the University of Pennsylvania for individuals who are in a position to control the content of an educational activity to disclose to the learners all relevant financial relationships that they have with any commercial interest that provides products or services that may be relevant to the content of this continuing medical education activity. Dr. Dickler discloses the following: Advisory Board: Amgen, AstraZeneca, BMS, Genentech/Roche, Genomic Health, Novartis, Syndax. Data Safety Monitoring Board: Eisai, Merrimack, Syndax Office of CME: Zalman S. Agus, MD has no relevant financial relationships to disclose. Mila Kostic has no relevant financial relationships to disclose. Medical Communications Media, Inc.: Sara Thier, PhD, MPH has no relevant financial relationships to disclose. Elizabeth Paczolt, MD has no relevant financial relationships to disclose. Investigational and/or Off-Label Use of Commercial Products and Devices: The Perelman School of Medicine at the University of Pennsylvania requires all faculty to disclose any planned discussion of an investigational and/or off-label use of a pharmaceutical product or device within their presentation. Participants should note that the use of products outside FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for approved indications. In this educational activity, the faculty discusses the use of new or investigational agents including: pertuzumab, T-DM1, everolimus, and iniparib. This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Perelman School of Medicine at the University of Pennsylvania and Medical Communications Media, Inc. The Perelman School of Medicine at the University of Pennsylvania is accredited by the ACCME to provide continuing medical education for physicians. The Perelman School of Medicine at the University of Pennsylvania designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Release date: January 24, 2012 Last review date: January 24, 2012 Expiration date: January 23, 2013 Supported by an educational grant from Genentech BioOncology. Completion Instructions 1. Accessing Activity: * Link to and Log into program on QuantiaMD.com * Take the pre-test * Review the activity * Take the post-test and score 100% * You are allowed two retakes * Complete the evaluation * View, print, or save a CME certificate verifying your credit/participation in this activity 2. Computer Requirements: Minimum System Requirements: • Pentium III, 600 MHz or Equivalent Processor • 512 MB of RAM • Windows XP, Vista, or 7 • Mac OS X • 800x600 Monitor Resolution • 16-bit Color • 16 bit Sound Card with Speakers $0.00 There is no charge for CME credit. © 2012, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher,the Perelman School of Medicine at the University of Pennsylvania, or Genentech BioOncology. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.